Mortality Rate and Years of Life Lost Due to Prostate Cancer in Yazd Province, Iran: A 10-year study

Mirzaei, Mahboubeh; Mirzadeh, Mahboobahsadat; Mehrara, Mohsen

doi:10.18295/squmj.2017.17.04.008

Cited by 10 publications

(10 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ten, to calculate YLL, using the table of standard age and determining life expectancy for diferent age and gender groups, in addition to the number of deaths due to hypertension, calculations were done in each gender and age groups based on the following formula [14]:…”

Section: Discussionmentioning

confidence: 99%

“…Then, to calculate YLL, using the table of standard age and determining life expectancy for different age and gender groups, in addition to the number of deaths due to hypertension, calculations were done in each gender and age groups based on the following formula [ 14 ]:

where N is the number of deaths in a specified age and gender group, L is the life expectancy of death cases again in that age and gender group, r is the discounting rate, which equals 0.03, β is a conventional rate in calculating age value which equals 0.04, C is an adjusted, constant value that equals 0.1658, a is the age on which death occurred, and e is a constant value considered as 2.71.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Mortality Rate and Years of Life Lost due to Hypertension in the South of Iran between 2004 and 2019: A Population-Based Study

Mirahmadizadeh

Vali

Hassanzadeh

et al. 2022

International Journal of Hypertension

View full text Add to dashboard Cite

Introduction. Hypertension is known worldwide as a preventable significant risk factor for cardiovascular diseases and their mortality. This study was designed to determine the mortality rate and years of life lost (YLL) due to hypertension in Fars Province. Method. In this cross-sectional study, we extracted all death reports due to hypertension based on age, gender, and the year of death based on ICD-10 from the EDRS system (Electronic Death Registration System). The YLL analysis due to premature death related to hypertension was executed by the 2015 YLL template from WHO in EXCEL 2016 software. To examine the trend of crude and standardized mortality rates and YLL rates for different years, joinpoint regression was used based on the log-linear model. Results. In the 16 years that the study was done (2004–2019), 13443 death cases occurred in the Fars Province, 51.0% of which (6859 cases) were in females and 48.5% (6515 cases) of which were in the 80+ age group. Total YLL due to hypertension in these 16 years of study was 61,344 (1.9 per 1000) in males, 64,903 (2.1 per 1000) in females, and 126,247 (2.0 in 1000) in both genders. According to the joinpoint regression analysis, the 16-year trend of YLL rate due to premature mortality was increasing: the average annual percent change (AAPC) was 4.9% (95% CI −2.6 to 12.85, p v a l u e = 0.205 ) for males and 8.4% (95% CI 5.2 to 11.7, p value <0.001) for females. Conclusion. Considering the increasing trend in crude and standardized mortality rates and YLL due to hypertension, it is important for policymakers and decision makers of Health Policy Centers to promote and inform people about the importance of hypertension control and to familiarize them with proper, preventive interventions such as the importance of a healthy diet, routine physical activity, and routine learning programs for different groups in the society especially for people at a higher risk of hypertension.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Mortality Rate and Years of Life Lost due to Hypertension in the South of Iran between 2004 and 2019: A Population-Based Study

Mirahmadizadeh

Vali

Hassanzadeh

et al. 2022

International Journal of Hypertension

View full text Add to dashboard Cite

show abstract

“…Therefore, calculating YLL can provide us with a meaningful index to evaluate the loss of society due to a disease. [ 16 ]…”

Section: Discussionmentioning

confidence: 99%

Years of life lost due to asthma in a population-based 10-year study in Yazd, Iran

2018

View full text Add to dashboard Cite

Introduction:Asthma is a prevalent disease in both children and adults. Significant progress in the management of asthma and prevention of asthmatic attacks resulted in a reduction of asthma deaths, but there is a variation among different regions based on health-care access and environmental factors. We aimed to investigate the trend of asthma mortality during a 10-year period in Yazd Province, a region in the center of Iran.Methods:We obtained our data from the death registry of Yazd health center. This registry collects data from hospitals, clinics, forensic medicine department, and cemeteries. All deaths due to asthma from 2002 to 2011 were included in our study. We used the remaining life expectancy of each person at death and sex group to calculate the years of life lost (YLL) due to asthma.Results:Nearly 10,371 years of life was lost due to asthma in our study (M/F ratio of 1.29). Asthma mortality rate increased with age, rising sharply after age 50. Average YLL per death was 18.6 years. Asthma mortality rate decreased from 6.66/100,000 in 2002 to 3.97 in 2011. YLL from asthma among men decreased from 796 in 2002 to 338 in 2011, but among women, it showed an increase from 335 to 534 at the same time.Conclusion:The trend of reduction in asthma mortality is not similar between different age and gender groups. Further studies are needed to determine the cause of increasing trend among more vulnerable groups.

show abstract

“…Prostate cancer remains the first cause of mortality in the United States [27]. In prostate tumor cells, GE administration inhibits growth and survival by downregulating the expression of transcription factor E2F8.…”

Section: Cytotoxic and Antitumor Activitiesmentioning

confidence: 99%

Pharmacological Properties of Geraniol – A Review

et al. 2018

View full text Add to dashboard Cite

Geraniol is an acyclic isoprenoid monoterpene isolated from the essential oils of aromatic plants including Cinnamomum tenuipilum, Valeriana officinalis, and several other plants. The limited source of geraniol from plant isolation cannot fulfill the great demand from the flavor and fragrance industries, which require maximizing geraniol production through biotechnology processes. The diverse activities of geraniol suggested that geraniol could treat various diseases as a promising drug candidate. In order to evaluate the potential of geraniol applied in a clinical trial, this review aims at providing a comprehensive summary of the pharmacological effects of geraniol. The publications retrieved from PubMed, ScienceDirect, Springer, and Wiley databases were collected and summarized for the last 6 years. Then, the potential application of geraniol as a drug is discussed based on its pharmacological properties, including antitumor, anti-inflammatory, antioxidative, and antimicrobial activities, and hepatoprotective, cardioprotective, and neuroprotective effects. Hence, this review aims at providing evidence of the pharmacological activities of geraniol in the context of further development as a drug candidate in clinical application.

show abstract

Mortality Rate and Years of Life Lost Due to Prostate Cancer in Yazd Province, Iran: A 10-year study

Cited by 10 publications

References 23 publications

Mortality Rate and Years of Life Lost due to Hypertension in the South of Iran between 2004 and 2019: A Population-Based Study

Mortality Rate and Years of Life Lost due to Hypertension in the South of Iran between 2004 and 2019: A Population-Based Study

Years of life lost due to asthma in a population-based 10-year study in Yazd, Iran

Pharmacological Properties of Geraniol – A Review

Contact Info

Product

Resources

About